This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
With the addition of Karsanbhai, the Merck board will consist of 13 members
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Subscribe To Our Newsletter & Stay Updated
